Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Dividend recapitalization, when a private company pays its investors a cash dividend with borrowed money, surged to a record ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Bain Capital entered a deal to acquire Mitsubishi Tanabe Pharma Corporation (MTPC) from Mitsubishi Chemical Group for 510 ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

The North Asian private equity giant cited rising demand for semiconductor products amid the AI boom for its decision to ...

Bain Capital has agreed to acquire Tanabe Pharma, the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe ...

Mitsubishi UFJ Morgan Stanley Securities and BofA Securities are serving as financial advisors, and Morrison Foerster, Mori, Hamada & Matsumoto and Ropes & Gray are serving as legal advisors to Bain ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical business for more than $3 billion, a deal that would allow the Japanese company to focus on its key chemical businesses.

Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.